Watch PCSA. Know when insiders buy.
One email the day a filing lands. Free.
PCSA
Processa Pharmaceuticals, Inc.
1.85
−0.04 −2.12%
USD · close Sep 24
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.2MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$13.4MNET CASH $169K52W 1.84 – 11.98SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$2.3M | −$3.3M | — | -1.19 | −$2M | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$3.3M | −$3.4M | — | -1.29 | −$3.6M | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$3.7M | −$3.4M | — | -9.95 | −$2.9M | — | — | Mar 18 |
| Q3 2025 · Sep 30 | — | — | — | −$3.5M | −$3.4M | — | -0.07 | −$3.5M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$4M | −$3.9M | — | -6.26 | −$2.3M | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$2.8M | −$2.8M | — | -7.58 | −$2.7M | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$2.7M | −$2.7M | — | -93.65 | −$2.2M | $0 | −$2.2M | Mar 18 |
| Q3 2024 · Sep 30 | — | — | — | −$3.4M | −$3.4M | — | -1.03 | −$3.6M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$3.1M | −$3M | — | -1.01 | −$3.3M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$2.8M | −$2.7M | — | -1.11 | −$2M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.5M | −$2.4M | — | -1.67 | −$2.1M | $0 | −$2.1M | Mar 20 |
| Q3 2023 · Sep 30 | $0 | — | — | −$2.2M | −$2.1M | — | -1.54 | −$1.8M | — | — | Oct 30 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$14M | −$13.6M | — | -10.36 | −$11.4M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$12.1M | −$11.9M | — | -96.78 | −$11.2M | $3K | −$11.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$11.5M | −$11.1M | — | -8.48 | −$8.1M | $3K | −$8.1M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$27.5M | −$27.4M | — | -34.05 | −$9.6M | — | — | — | — |
| FY2021 · to Dec 31 | $0 | — | −$12.1M | −$11.4M | — | -0.75 | −$8.7M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$15.1M | −$14.4M | — | -2.54 | −$3.1M | — | — | — | — |
Every number comes from Processa Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.